Amgen US stocks surged more than 14% ahead of the market, and the mid-term trial of its new weight loss drug received positive data. If the drug is approved, it will compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.